CN102960715A - Immunity-enhancing and hypoxia tolerant health food and preparation method thereof - Google Patents
Immunity-enhancing and hypoxia tolerant health food and preparation method thereof Download PDFInfo
- Publication number
- CN102960715A CN102960715A CN201210329693XA CN201210329693A CN102960715A CN 102960715 A CN102960715 A CN 102960715A CN 201210329693X A CN201210329693X A CN 201210329693XA CN 201210329693 A CN201210329693 A CN 201210329693A CN 102960715 A CN102960715 A CN 102960715A
- Authority
- CN
- China
- Prior art keywords
- health food
- mouse
- anoxic
- immunity
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses an immunity-enhancing and hypoxia tolerant health food, which comprises the following components by weight: 15-35% of American ginseng, 20-45% of panax notoginseng and 20-45% of cordyceps sinensis. At the same time, the invention also discloses a preparation method of the health food. The health food adopts traditional Chinese medicines and medicinal food as the main raw materials, achieves the functions of immunity enhancement, hypoxia tolerance and fatigue resistance simultaneously, and has no side effect, thus being suitable for people of all ages.
Description
Technical field
The invention belongs to field of health care products, be specifically related to a kind of health food that has simultaneously raising immunity and resisting oxygen lack and preparation method thereof.
Background technology
Modern society, the pressure of people's work, study increases day by day, causes easily the symptoms such as people's hypoimmunity, large cerebral anoxia.
During hypoimmunity, can reduce body to anti-infectious ability, reduce identification and remove the histocyte ability of self aging, reduce and kill and wound and remove abnormal sudden change cell ability in vivo, cause the decline of human body premunition and vis medicatrix naturae.And when brain often is in anaerobic condition, can reduce the quality of study, work, make simultaneously body be in for a long time sub-health state.
Want fundamentally to prevent inferior health, optimal way is when strengthening physical training, and notes self health care, reasonable edible health food, thus make health reach best immunity and anti-anaerobic condition.Therefore, developing safely and effectively, health food is a popular exercise question.
Summary of the invention
Goal of the invention: the object of the invention is to, for the deficiencies in the prior art, provide a kind of health food that improves immunity and resisting oxygen lack that has simultaneously.
Another object of the present invention is to, the preparation method of above-mentioned health food is provided.
Technical scheme: in order to achieve the above object, the present invention specifically is achieved like this: a kind of have a health food that improves immunity, anti-anoxic, comprises the component of following percentage by weight: 15 ~ 35% American Ginseng, 20 ~ 45% pseudo-ginseng and 20 ~ 45% Cordyceps sinensis.
Wherein, in order to reach better goal of the invention, the preferred assembly side of the present invention is 5 ~ 35% American Ginseng, 20 ~ 45% pseudo-ginseng, 20 ~ 45% Cordyceps sinensis, 5 ~ 15% tea extract, 5 ~ 10% hippophae rhamnoides, 5 ~ 10% Abelmoschus Esculentus Linn extract and 5 ~ 10% Shorthorned Epimedium P.E for containing percentage by weight.
Wherein, described Cordyceps sinensis is natural cordyceps, paecilomycerol bat moth mycelium or Hirsutella sinensis mycelium.
Wherein, American Ginseng can be replaced by ginseng in the described health products.
Wherein, described American Ginseng is the American Ginseng alcohol extract, and through pulverizing, 70% alcohol reflux extracts by American Ginseng, and extract is concentrated, and drying is pulverized, and sieves and obtains.
Wherein, described tea extract is to be got through water extraction by green tea, and extract is concentrated, gets the concentrate alcohol precipitation, and pure hypostasis is dry, pulverizes, and sieves and obtains.
Finished dosage forms of the present invention can be made into tablet, mixture, powder, granule or capsule.
Simultaneously, the present invention also has the function of antifatigue.
The above-mentioned method with the health food that improves immunity, anti-anoxic of preparation power may further comprise the steps:
(1) measures each raw material by prescription, cross 80 mesh sieves, mixed 20 minutes;
(2) raw material that mixes is inserted capsule, every 0.4g.
Beneficial effect: it is main material that the present invention adopts Chinese medicine and medicinal food, also has the functions such as anti-anoxic, antifatigue when reaching raising immunity, simultaneously without any side effects, is fit to all age group crowd and uses.
The specific embodiment
Embodiment 1:
Get percetage by weight and be 15% American Ginseng, 40% pseudo-ginseng and 45% Cordyceps sinensis, cross 80 mesh sieves, mixed 20 minutes, after insert capsule, every 0.4g.
Embodiment 2:
Get percetage by weight and be 15% ginseng, 45% pseudo-ginseng and 40% Cordyceps sinensis, cross 80 mesh sieves, mixed 20 minutes, after insert capsule, every 0.4g.
Embodiment 3:
Get percetage by weight and be 30% American Ginseng, 20% pseudo-ginseng, 20% Cordyceps sinensis, 5% tea extract, 10% hippophae rhamnoides, 5% Abelmoschus Esculentus Linn extract, 5% gadol extract and 5% Shorthorned Epimedium P.E, cross 80 mesh sieves, mixed 20 minutes, after insert capsule, every 0.4g.
Embodiment 4:
Get percetage by weight and be 15% ginseng, 20% pseudo-ginseng, 20% Cordyceps sinensis, 15% tea extract, 5% hippophae rhamnoides, 5% gadol extract, 10% Abelmoschus Esculentus Linn extract and 10% Shorthorned Epimedium P.E, cross 80 mesh sieves, mixed 20 minutes, after insert capsule, every 0.4g.
Embodiment 5:
The present invention increases the immunity function experimental study
1. material
1.1 sample: provided by the Wuxi health bio tech ltd of being bestowed by heaven.
1.2 animal used as test
160 of Kunming mouses, entirely female, body weight 18-22g.
2. experimental technique
2.1 dosage is selected
Tested material is established 400mg/kg.BW, 800mg/kg.BW, three dosage groups of 1200 mg/kg.BW (be equivalent to respectively human body recommended intake 10 times, 20 times, 30 times), take by weighing respectively 10.00g, 20.00g, 30.00g tested material adding distil water to the 250ml mixing, stored refrigerated, be finished again and join, other establishes the edible vegetable oil negative control group, every group of 40 animals.Be divided into immune one group, two groups, three groups, four groups, wherein one group is used for Turnover of Mouse Peritoneal Macrophages and engulfs the chicken red blood cell experiment; Two groups are used for NK cytoactive detection and lymphocyte transformation experiment; Three groups are used for antibody-producting cell experiment, serum hemolysin mensuration and delayed allergy; Four groups are used for mouse carbon and clean up experiment.Mouse gives 30 days continuously by per os gavage of 10 mg/kg.BW body weight, claims weekly body weight one time, adjusts the gavage volume.
2.2 experimental procedure
2.2.1 mouse carbon clearance test: gavage is after 30 days continuously, in the india ink of mouse tail vein injection with 4 times of normal saline dilutions, immediately timing after pressing 0.1ml/10g prepared Chinese ink and injecting is after injecting prepared Chinese ink the 2nd, 10min gets blood 20 μ l from the angular vein clump respectively, is added to 2mlNa
2CO
3In the solution, with Na
2CO
3Solution is made blank, measures OD value at the 600nm place with 723 spectrophotometers.Put to death mouse after getting blood, get liver, spleen is weighed, calculate phagocytic index.
2.2.2 Turnover of Mouse Peritoneal Macrophages is engulfed chicken red blood cell experiment (half intracorporal method): gavage is after 30 days continuously, the chicken erythrocyte suspension 1ml of every mouse peritoneal injection 20%, after 30 minutes, the cervical vertebra dislocation is put to death, be fixed on the mouse plate, abdominal skin is cut off in the center, through Intraperitoneal injection physiological saline 2ml, rotated the mouse plate 1 minute, sucking-off abdominal cavity washing lotion 1ml, mean droplet is on 2 slides, put 37 ℃ in wet box 30 minutes, and took out in the physiological saline rinsing, dry, fixing, 4%GiemsaPBS dyeing 3 minutes, the distilled water rinsing is dried, microscopy.Calculate phagocytic percentage and phagocytic index.
2.2.3 delayed allergy (DTH) (the sufficient sole of the foot thickens method): gavage is after 30 days, inject the every mouse of 2% hematocrit SRBC(0.2ml/ to mouse peritoneal) sensitization is after 4 days, measure left back sufficient sole of the foot thickness, and then measuring point hypodermic injection 20%(v/v) the every mouse of SRBC(20 μ l/), 24h measures left back sufficient sole of the foot thickness after injection, same position is measured three times, averages, and represents the degree of DTH with sufficient sole of the foot thickness difference (swelling degree of the paw) before and after attacking.
2.2.4ConA the mouse lymphocyte conversion test (mtt assay) of inducing: at first carry out the preparation of splenocyte suspension.Cell concentration is adjusted into 3 * 10
6Individual/ml, then cell suspension is divided two holes to add in 24 well culture plates, every hole 1ml, a hole adds 75 μ lConA liquid, and another hole compares, and puts 5%CO
237 ℃ of cultivations of incubator 72h.Cultivate and finish front 4h, every hole sucks gently supernatant 0.7ml and adds the RPMI1640 nutrient solution that 0.7ml does not contain calf serum, add simultaneously MTT (5mg/ml) 50 μ l/ holes and continue to cultivate 4h, after cultivating end, every hole adds 1ml acid isopropyl alcohol, purple crystal is dissolved fully, then every hole liquid is moved in the cuvette, with 723 spectrophotometers in 570nm wavelength place's colorimetric estimation OD value.
2.2.5 antibody-producting cell detects (Jernr improves slide method): gavage is after 30 days continuously, every mouse peritoneal is injected 2% hematocrit SRBC0.2ml, the mouse cervical vertebra dislocation of immunity after 5 days half put to death, take out spleen and be placed in the plate that fills Hank ' s liquid, make splenocyte suspension.Agarose is made into 1% aqueous solution, and 30min is boiled in water-bath, mix with the double Hank ' s of equivalent liquid, and the packing small test tube, every pipe 0.5ml adds 10%(S again in pipe
AThe buffer solution preparation) hematocrit SRBC50 μ l, each 20 μ l of splenocyte suspension do two Duplicate Samples, rapidly behind the mixing, be poured on the agarose thin layer slide, after agar solidifies, the slide level buckled be placed on the horse, put into CO2gas incubator and hatch 1.5h, then complement is joined in the slide frame groove, continue incubation 1.5h, counting hemolysis plaque number.
2.2.6 serum hemolysin is measured (Hemagglutination Method): in continuous gavage after 30 days, every mouse peritoneal injection 2%SRBC0.2ml immunity, continue gavage after 5 days, extract eyeball and get blood in centrifuge tube, place 1h, peel off, the centrifugal 10min of 2000r/min collects serum, with physiological saline serum is made doubling dilution, every part of dilution 12 holes place blood-coagulation-board with the dilution serum of difference, every hole 100 μ l, add again 0.5%SRBC suspension 100 μ l, mixing is put observed result behind wet 37 ℃ of 3h of box, records the aggegation degree in every hole.The calculating antibody product.
2.2.7NK cytoactive detection (lactate dehydrogenase L DH determination method): continuously gavage is after 30 days, and animal is put to death in the cervical vertebra dislocation, takes out spleen, tears up, cross 200 eye mesh screens after, use Hank ' s liquid to wash 3 times, be made into 2 * 10 with complete RPMI1640 nutrient solution
7Individual/the ml cell suspension.The cell suspension of each mouse is got 300 μ l divide 3 holes to place 96 well culture plates, every hole 100 μ l, every hole adds target cell (YAC-1 cell, 4 * 10
5Individual/ml) 100 μ l, do simultaneously each 8 hole of target cell Spontaneous release hole (target cell 100 μ l+ nutrient solutions 100 μ l) and maximum release aperture (target cell 100 μ l+2.5%Triton100 μ l), 37 ℃ of 5%CO
2Cultivated 4 hours, and took out the centrifugal 5min of 1500r/min.Each hole supernatant 100 μ l is placed another culture plate, and every hole adds 100 μ l matrix liquid again, adds the HCL30 μ l cessation reaction of 1mol/L after 10 minutes, measures the OD value at the 490nm place, calculates NK cytoactive rate.
3. test data is added up
Test data adopts SPSS10.0 for Windows software kit to process.The data of control group and dosage group are through the variance test of homogeneity, and variance is neat, carry out variance analysis,, then compare in twos with the Dunnett method less than 0.05 such as the P value; If heterogeneity of variance then carries out data transaction, and is still uneven, use rank test instead, less than 0.05, then use Dunnett ' sT3 method to compare in twos (P〉0.05 for non-significant difference, P＜0.05 is significant difference) such as the P value.
4. result
4.1 the present invention sees Table 1-4 to the impact of Mouse Weight.
Table 1 respectively organize mouse initial body weight (
)
Table 2 respectively organize mouse the body weight in mid-term (
)
Table 3 respectively organize mouse the end body weight (
)
The impact that table 4 the present invention increases weight on Mouse Weight (
)
By table 1-4 as seen, the initial body weight of one group, immune two groups of the present invention immunity, immune three groups and immune four groups of mouse is compared with negative control group, through the variance test of homogeneity, variance neat (P〉0.05), and the results of analysis of variance (P〉0.05), illustrate that the initial body weight of respectively organizing between mouse and the negative control group is balanced.Three dosage group mouse test mid-terms, the body weight in latter stage and the growths of duration of test Mouse Weight are compared with negative control group, learn by statistics and process, there was no significant difference (P〉0.05), i.e. the present invention on the body weight gain of mouse without impact.
4.2 the present invention is on the impact of mouse monokaryon-macrophage phagocytic function
Table 5 the present invention on mouse monokaryon-macrophage carbon clean up function impact (
)
By as seen from Table 5, gavage is after 30 days continuously, and the carbon of three dosage group mouse is cleaned up ability and compared with negative control group, and learn by statistics and process, there was no significant difference (P〉0.05).
Table 6 the present invention on mouse macrophage engulf the chicken red blood cell ability impact (
)
By as seen from Table 6, gavage is after 30 days continuously, and the phagocytic rate of three dosage treated animals is compared with negative control group with phagocytic index, learns by statistics and processes, and middle and high dosage group phagocytic index has significant difference (P＜0.05).
By table 5, as seen from Table 6, the present invention is positive to mouse monokaryon-macrophage phagocytic function test result.
4.3 the present invention is on the impact of mouse cell immunity
Table 7 the present invention on the impact of mouse delayed allergy (DTH) (
)
By as seen from Table 7, gavage is after 30 days continuously, and the swelling degree of the paw of three dosage group mouse is compared with negative control group, and learn by statistics and process, there was no significant difference (P〉0.05)
The impact of the mouse lymphocyte conversion test that table 8 the present invention induces ConA (
)
By as seen from Table 8, the gavage mouse is after 30 days continuously, and the lymphopoiesis ability of three dosage group mouse is compared with negative control, and learn by statistics and process, there was no significant difference (P〉0.05).
By table 7, the present invention is negative to mouse cell immunity test result as seen from Table 8.
4.4 the present invention is on the impact of mouse humoral immune
Table 9 the present invention on the impact of mouse antibodies cellulation (
)
By as seen from Table 9, gavage is after 30 days continuously, and the hemolysis plaque number of three dosage group mouse is compared with negative control, learns by statistics and processes, and low, middle dosage group has significant difference (P＜0.05).
Table 10 the present invention on the impact of mice serum hemolysin (
)
By as seen from Table 10, gavage is after 30 days continuously, and the antibody product of three dosage group mouse is compared with negative control group, learns by statistics and processes, and low dose group has utmost point significant difference (P＜0.05)
By table 9, as seen from Table 10, the present invention is positive to the mouse humoral immune result of the test.
4.5 the present invention is on the impact of NK cells in mice activity
Table 11 the present invention on the impact of NK cells in mice activity (
)
By as seen from Table 11, gavage is after 30 days continuously, and three dosage group NK cells in mice activity are compared with negative control, and learn by statistics and process, there was no significant difference (P〉0.05).The present invention is aobvious negative to the NK cytoactive result of the test of mouse.
5. sum up
The continuous gavage mouse of the present invention had no significant effect Mouse Weight after 30 days; Test for celluar immunity result to mouse is negative; NK test cell line result to mouse is negative; To the test for humoral immunity of mouse, the hemolysis plaque number of three dosage groups and negative control group compare, and low, middle dosage group difference all has conspicuousness (P＜0.05), and result of the test is positive; To the monocytes/macrophages phagocytic function test of mouse, the phagocytic rate of three dosage group mouse and phagocytic index and negative control group compare, and middle and high dosage group difference has conspicuousness (P＜0.05), and result of the test is positive.
Can judge that according to " health food check and assessment technique standard " version in 2003 the present invention has the function that increases immunity to animal.
Embodiment 6:
The present invention improves the stressed function zoopery of anti-anoxic
1 sample and method
1.1 sample is provided by the Wuxi City health bio tech ltd of being bestowed by heaven.
1.2 120 of animal used as test male mice in kunming, body weight 18 ~ 20g.
1.3 it is 50ml/60kgBW that dosage is selected human body recommended amounts every day, 2 times of concentrates of this experiment employing are established 4.17ml/60kgBW, 8.33ml/60kgBW, three dosage groups of 12.50ml/60kgBW (be equivalent to respectively human body recommended amounts 10,20,30 times).Measure respectively 2 times of concentrate 52.1ml, 104.2ml, 156.3ml, each adding distil water is settled to the 250ml mixing, and refrigerator-freezer is preserved, and is finished and joins, and other establishes the distilled water control group.Experiment is divided into one, two, three group, every group of 40 animals.
1.4 experimental technique
1.4.1 with distillation water as solvent preparation tested material, press once a day per os gavage mouse of 20ml/60kgBW, give continuously 30 days.
1.4.2 the normal pressure hypoxia endurance test will be tested the animal last of one group of each dosage group and give after the tested material 1 hour, each dosage group mouse is put into respectively the 250ml port grinding bottle (1 every bottle) that fills the 5g soda lime, seal bottleneck with vaseline, cover tightly, make it air tight, immediately timing take breath stopped as index, is observed mouse because of the anoxic Post-dead duration.
1.4.3 natrium nitrosum poisoning survival test will be tested the animal last of two groups of each dosage groups and give after the tested material 1 hour, with each dosage group mouse by 220mg/60kgBW dosage lumbar injection natrium nitrosum (injection volume is 0.1ml/10g), immediately timing, the record animals survived time.
1.4.4 the Ischemia Injury in Brain hypoxia test will be tested the animal last of three groups of each dosage groups and give after the tested material 1 hour, with each dosage group mouse from neck by broken end only, immediately by behind the stopwatch record mouse broken end to the dwell time of breathing of dehiscing.
1.5 the data statistics of test data statistical test adopts SPSS 11.0 for windows software kits to process, data are through the variance test of homogeneity, and variance is neat, carries out variance analysis,, then compares in twos with the Dunnett method less than 0.05 such as the P value; If heterogeneity of variance then carries out data transaction, and is still uneven, use rank test instead,, then compare in twos with the Dunnett'sT3 method less than 0.05 such as the P value.
2 results
2.1 the present invention is on the impact of Mouse Weight
By table 12,13,14 as seen, the initial body weight of each dosage group and control animals is learned processing by statistics, variance neat (P〉0.05), and the results of analysis of variance (P〉0.05), show that the initial body weight of each treated animal is balanced.Body weight and control group were relatively learned by statistics and are processed when the mid-term of three dosage treated animals, body weight was with end, difference that there are no significant (P〉0.05).
Table 12 take the present invention respectively organize the initial body weight of mouse (
)
Table 13 take the present invention respectively organize mouse body weight in mid-term (
)
Table 14 take the present invention respectively organize mouse finish body weight (
)
2.2 the present invention is on the impact of mouse Hypoxia under normal pressure
By as seen from Table 15, the mouse Hypoxia under normal pressure of three dosage groups and control group are relatively learned by statistics and are processed, difference that there are no significant (P〉0.05).
Table 15 take the present invention on the impact of mouse Hypoxia under normal pressure (
)
2.3 the present invention is on the impact of poisoning time-to-live of mouse natrium nitrosum
By as seen from Table 16, the mouse natrium nitrosum poisoning time-to-live of three dosage groups and control group are relatively, learn to process by statistics, go out middle dosage group there was no significant difference outer (P〉0.05), poisoning prolonged survival period low, high dose group has significant difference (P＜0.05).
Table 16 take the present invention on the mouse natrium nitrosum poison the time-to-live impact (
)
2.4 the present invention is on the impact of anoxic time of chmice acute cerebral ischemia
By as seen from Table 17, the chmice acute cerebral ischemia the survival time under hypoxic condition of three dosage groups and control group are relatively learned by statistics and are processed, the Ischemia Injury in Brain the survival time under hypoxic condition of basic, normal, high dosage group prolongs all significant difference (P 0.05).
Table 17 take the present invention on the impact of anoxic time of chmice acute cerebral ischemia (
)
3 brief summaries
After continuous 30 days per os gavages of the present invention gave male mice, visible growth of animal was good, the body weight sustainable growth.The result is negative for the normal pressure hypoxia endurance test; Low, high dose group can obviously prolong natrium nitrosum and poison the time-to-live, and the result is positive for natrium nitrosum poisoning survival test; Basic, normal, high dosage group can obviously prolong chmice acute cerebral ischemia the survival time under hypoxic condition, the result is positive to the Ischemia Injury in Brain hypoxia test, by the regulation in " health food check and assessment technique standard " (version in 2003), the present invention has the raising anoxia tolerant function to animal.
Embodiment 7:
The research of anti-fatigue effect of the present invention
1. material
1.1 sample: provided by the Wuxi health bio tech ltd of being bestowed by heaven, the human body recommended amounts was 0.45 * 4/ people/day (30mg/kg.bw).
1.2 animal used as test
SPF level male ICR mouse, body weight 19 ~ 22g.
2. experimental technique
2.1 dosage is selected
Animal used as test is divided into blank group and 3 test group of the present invention at random.Tested material dosage is respectively 300mg/kg.bw, 600 mg/kg.bw, 900 mg/kg.bw(and is equivalent to respectively 10,20 and 30 times of human body recommended intake).Gavage liquid preparation: take by weighing 0.6g, 1.2g and 1.8g sample of the present invention, be dissolved in respectively in the 40ml distilled water, by 20 mg/kg.bw gavages.The blank treated animal is with the distilled water gavage, and each experimental group animal is with the distilled water solution gavage of corresponding dosage, and once a day, gavage was tested after 30 days continuously
2.2 experimental procedure
2.2.1 swimming with a load attached to the body experiment: after last gives tested material 30min, the load mouse of 5% body weight sheet lead of afterbody is placed the swimming trunk went swimming.Many and the 30cm of the depth of water in the case, 25 ± 1 ℃ of water temperatures, mouse begins to Post-dead duration from swimming record.
2.2.2 blood Plasma lactate: after last gave tested material 30min, it was not swimming with a load attached to the body 10min in 30 ℃ the water that animal is put temperature, and before swimming, after the swimming immediately, rest 20min respectively adopts eyeball blood 20 μ L mensuration lactic acid content after the swimming.And by following formula calculating blood lactic acid TG-AUC, to judge the rear blood lactic acid situation of change of motion.Blood lactic acid TG-AUC=5 * (rest 20min blood Lactate after 0min blood Lactate+2 after blood Lactate before the swimming+3 * swimming * swimming)
2.2.3 serum urea nitrogen determination: after last gives tested material 30min, it is not swimming with a load attached to the body 90min in 30 ℃ the water that mouse is put temperature, adopt eyeball blood 0.5mL behind the rest 60min, get serum after the blood clotting and measure the serum urea nitrogen content with Olympus AU400 type automatic biochemistry analyzer.
2.2.4 hepatic glycogen is measured: give tested material 30min in last and put to death animal, get liver and after the physiological saline rinsing, blot with filter paper, take by weighing rapidly liver 100mg, measure hepatic glycogen content (anthrone method).
3. experimental data is added up
Experimental data is carried out variance analysis with PEMS for Windows3.0 statistical package; The heterogeneity of variance data are carried out suitable variable conversion; If do not reach yet the neat person of variance after the variable conversion, add up with rank test.
4 results
4.1 the present invention is on the impact of Mouse Weight
Table 18 the present invention on the impact (swimming with a load attached to the body experiment) of Mouse Weight (
)
| Group | Dosage | Number of animals | Initial body weight | Mid-term body weight | Finish body weight |
| （mg/kg.BW） | (only) | （g） | （g） | （g） | |
| The blank group | 0 | 10 | 20.3±1.2 | 34.6±3.2 | 38.7±5.4 |
| Low dose group | 300 | 10 | 20.5±1.3 | 35.5±2.5 | 40.1±2.8 |
| Middle dosage group | 600 | 10 | 20.5±1.2 | 36.2±2.1 | 40.2±3.6 |
| High dose group | 900 | 10 | 20.5±1.1 | 35.3±3.3 | 39.2±3.4 |
Table 19 the present invention on the impact (blood Plasma lactate) of Mouse Weight (
)
| Group | Dosage | Number of animals | Initial body weight | Mid-term body weight | Finish body weight |
| （mg/kg.BW） | (only) | （g） | （g） | （g） | |
| The blank group | 0 | 10 | 20.4±1.0 | 35.6±2.2 | 39.6±3.5 |
| Low dose group | 300 | 10 | 20.4±1.0 | 33.5±2.7 | 36.8±3.2 |
| Middle dosage group | 600 | 10 | 20.4±1.0 | 34.7±1.6 | 39.5±2.2 |
| High dose group | 900 | 10 | 20.4±1.0 | 34.4±3.4 | 37.7±4.1 |
Table 20 the present invention on the impact (determination of urea nitrogen) of Mouse Weight (
)
| Group | Dosage | Number of animals | Initial body weight | Mid-term body weight | Finish body weight |
| （mg/kg.BW） | (only) | （g） | （g） | （g） | |
| The blank group | 0 | 10 | 20.1±1.1 | 34.4±2.7 | 38.2±4.4 |
| Low dose group | 300 | 10 | 20.1±1.2 | 34.3±1.8 | 37.7±2.2 |
| Middle dosage group | 600 | 10 | 20.2±1.1 | 35.2±2.6 | 38.2±3.3 |
| High dose group | 900 | 10 | 20.2±1.0 | 33.6±2.6 | 37.8±2.4 |
[0147]Table 21 the present invention on the impact (hepatic glycogen mensuration) of Mouse Weight (
)
| Group | Dosage | Number of animals | Initial body weight | Mid-term body weight | Finish body weight |
| （mg/kg.BW） | (only) | （g） | （g） | （g） | |
| The blank group | 0 | 10 | 20.4±1.0 | 34.5±3.3 | 39.2±4.0 |
| Low dose group | 300 | 10 | 20.4±1.0 | 34.8±3.6 | 38.8±4.3 |
| Middle dosage group | 600 | 10 | 20.4±1.0 | 33.7±3.2 | 37.6±4.1 |
| High dose group | 900 | 10 | 20.4±1.0 | 33.6±1.4 | 36.9±2.2 |
Body weight there was no significant difference when by table 18 ~ 21 as seen, the initial body weight of mouse, experiment body weight in mid-term and experiment finish between three dosage combinations of the present invention blank group (P〉0.05).Show the present invention on Mouse Weight without impact.
4.2 the present invention is on the impact of mice burden swimming time
Table 22 the present invention on the impact of mice burden swimming time (
)
By as seen from Table 22, dosage group and high dose group mice burden swimming time significantly are longer than blank group (P＜0.05) among the present invention.
4.3 the present invention is on the impact of Mouse Blood lactic acid content
Table 23 the present invention on the impact of Mouse Blood lactic acid content (
)
By as seen from Table 23, each dosage group of the present invention swim rear three time point blood lactic acid TG-AUCs and blank group there was no significant difference (P〉0.05).
4.4 the present invention is on the impact of mice serum urea nitrogen content
Table 24 the present invention on the impact of mice serum urea nitrogen content (
)
By as seen from Table 24,3 dosage groups of the present invention serum urea nitrogen content significantly is lower than blank group (P＜0.05).
4.5 the present invention is on the impact of Mouse Liver glycogen content
Table 25 the present invention on the impact of Mouse Liver glycogen content (
)
By as seen from Table 25, low dose group hepatic glycogen content of the present invention is significantly higher than blank group (P＜0.05).
5. sum up
The present invention significantly is longer than blank group (P＜0.05) the middle and high dosage group mice burden swimming time; Basic, normal, high three dosage group serum urea nitrogen contents significantly are lower than blank group (P＜0.05, P＜0.01); The low dose group hepatic glycogen content is significantly higher than blank group (P＜0.05).Can judge that according to " health food check and assessment technique standard " version in 2003 the present invention has the function of alleviating physical fatigue.
Claims (9)
1. one kind has the health food that improves immunity, anti-anoxic, it is characterized in that, comprises the component of following percentage by weight: 15 ~ 35% American Ginseng, 20 ~ 45% pseudo-ginseng and 20 ~ 45% Cordyceps sinensis.
2. according to claim 1 have a health food that improves immunity, anti-anoxic, it is characterized in that, comprise that also percentage by weight is 5 ~ 15% tea extract, 5 ~ 10% hippophae rhamnoides, 5 ~ 10% gadol extract, 5 ~ 10% Abelmoschus Esculentus Linn extract and 5 ~ 10% Shorthorned Epimedium P.E.
3. the health food with raising immunity, anti-anoxic according to claim 1 and 2 is characterized in that described Cordyceps sinensis is natural cordyceps, paecilomycerol bat moth mycelium or Hirsutella sinensis mycelium.
4. the health food with raising immunity, anti-anoxic according to claim 1 is characterized in that described American Ginseng is replaced by ginseng.
5. according to claim 1 have a health food that improves immunity, anti-anoxic, it is characterized in that described American Ginseng is the American Ginseng alcohol extract, and through pulverizing, 70% alcohol reflux extracts by American Ginseng, and extract is concentrated, and drying is pulverized, and sieves and obtain.
6. according to claim 2 have a health food that improves immunity, anti-anoxic, it is characterized in that described tea extract is to be got through water extraction by green tea, and extract is concentrated, gets the concentrate alcohol precipitation, and pure hypostasis is dry, pulverizes, and sieves and obtain.
7. the health food with resisting oxygen lack according to claim 1 and 2 is characterized in that, finished dosage forms is tablet, mixture, powder, granule or capsule.
8. the health food with resisting oxygen lack according to claim 1 and 2 is characterized in that, has the function of antifatigue.
9. preparation claim 1 or 2 described methods with the health food that improves immunity, anti-anoxic is characterized in that, may further comprise the steps:
(1) measures each raw material by prescription, cross 80 mesh sieves, mixed 20 minutes;
(2) raw material that mixes is inserted capsule, every 0.4g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210329693XA CN102960715A (en) | 2012-09-07 | 2012-09-07 | Immunity-enhancing and hypoxia tolerant health food and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210329693XA CN102960715A (en) | 2012-09-07 | 2012-09-07 | Immunity-enhancing and hypoxia tolerant health food and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102960715A true CN102960715A (en) | 2013-03-13 |
Family
ID=47791371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210329693XA Pending CN102960715A (en) | 2012-09-07 | 2012-09-07 | Immunity-enhancing and hypoxia tolerant health food and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102960715A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103169746A (en) * | 2013-03-21 | 2013-06-26 | 中国中医科学院广安门医院 | Traditional Chinese medicine composition for treating lung cancer |
| CN104970369A (en) * | 2015-08-05 | 2015-10-14 | 海南正康药业有限公司 | Health food capable of enhancing immunity and preparation method of health food |
| CN105055577A (en) * | 2015-09-06 | 2015-11-18 | 青海之也科技咨询服务有限公司 | Health cordyceps sinensis tablet and preparation method |
| CN106074656A (en) * | 2016-07-27 | 2016-11-09 | 江苏七O七天然制药有限公司 | A kind of Chinese medicinal capsule and preparation technology thereof |
| CN107495367A (en) * | 2017-08-24 | 2017-12-22 | 四川省中医药科学院 | A kind of food, health products or pharmaceutical composition for improving hypoxia-bearing capability and its production and use |
| CN107927774A (en) * | 2017-10-24 | 2018-04-20 | 青海鑫池源生物科技开发有限公司 | A kind of health rhodiola capsule and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1335141A (en) * | 2000-07-26 | 2002-02-13 | 雷学军 | Antiaging water containing natural medicinal component and its prepn |
| CN101467673A (en) * | 2007-12-29 | 2009-07-01 | 沃德（天津）营养保健品有限公司 | Compound ginseng health product and preparation method thereof |
| CN101856120A (en) * | 2010-03-23 | 2010-10-13 | 无锡市天赐康生物科技有限公司 | Health food for improving immunity of human body and preparation method thereof |
| CN101862415A (en) * | 2010-03-25 | 2010-10-20 | 陈建新 | Method for preparing nutritious liquor |
| CN102302210A (en) * | 2011-07-20 | 2012-01-04 | 郭景龙 | Beverage with anti-fatigue effect |
-
2012
- 2012-09-07 CN CN201210329693XA patent/CN102960715A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1335141A (en) * | 2000-07-26 | 2002-02-13 | 雷学军 | Antiaging water containing natural medicinal component and its prepn |
| CN101467673A (en) * | 2007-12-29 | 2009-07-01 | 沃德（天津）营养保健品有限公司 | Compound ginseng health product and preparation method thereof |
| CN101856120A (en) * | 2010-03-23 | 2010-10-13 | 无锡市天赐康生物科技有限公司 | Health food for improving immunity of human body and preparation method thereof |
| CN101862415A (en) * | 2010-03-25 | 2010-10-20 | 陈建新 | Method for preparing nutritious liquor |
| CN102302210A (en) * | 2011-07-20 | 2012-01-04 | 郭景龙 | Beverage with anti-fatigue effect |
Non-Patent Citations (1)
| Title |
|---|
| 程启坤: "《茶的营养与保健》", 31 July 2005, article "茶多糖的提取分离", pages: 197 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103169746A (en) * | 2013-03-21 | 2013-06-26 | 中国中医科学院广安门医院 | Traditional Chinese medicine composition for treating lung cancer |
| CN104970369A (en) * | 2015-08-05 | 2015-10-14 | 海南正康药业有限公司 | Health food capable of enhancing immunity and preparation method of health food |
| CN105055577A (en) * | 2015-09-06 | 2015-11-18 | 青海之也科技咨询服务有限公司 | Health cordyceps sinensis tablet and preparation method |
| CN106074656A (en) * | 2016-07-27 | 2016-11-09 | 江苏七O七天然制药有限公司 | A kind of Chinese medicinal capsule and preparation technology thereof |
| CN107495367A (en) * | 2017-08-24 | 2017-12-22 | 四川省中医药科学院 | A kind of food, health products or pharmaceutical composition for improving hypoxia-bearing capability and its production and use |
| CN107927774A (en) * | 2017-10-24 | 2018-04-20 | 青海鑫池源生物科技开发有限公司 | A kind of health rhodiola capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103169079A (en) | Health-care food with anti-fatigue and immunity-enhancing effects, and preparation method thereof | |
| CN102960715A (en) | Immunity-enhancing and hypoxia tolerant health food and preparation method thereof | |
| CN104666996B (en) | Refresh oneself antifatigue Chinese medicine composition and preparation method and application | |
| CN101856120A (en) | Health food for improving immunity of human body and preparation method thereof | |
| CN103343083A (en) | Liver protecting and hangover alleviating fruit vinegar and preparation method thereof | |
| CN103300446A (en) | Functional blueberry beverage composition | |
| CN101248880B (en) | Fatigue resistant sport drink and method of preparing the same | |
| CN103829234A (en) | Health food capable of improving immunity and reducing blood fat and preparation method thereof | |
| CN101856112A (en) | Health food for enhancing immune function of human body and preparation method thereof | |
| CN101574151A (en) | Nutritional food with function of strengthening immunity and preparation method thereof | |
| CN102871120A (en) | Heath-care food for improving human immunity and preparation method thereof | |
| CN103584091B (en) | A kind of guarantor with raising immunity, hypolipemic function builds food and preparation method thereof | |
| CN103238889A (en) | Anti-fatigue apple vinegar health beverage and preparation method thereof | |
| CN102860496B (en) | Oxidation-resisting health-care food for improving immunity and preparation method thereof | |
| CN103039977A (en) | Healthcare food with functions of immunity improvement and hypoxia tolerance and preparation method thereof | |
| CN111467468A (en) | Concentrated nutrient solution containing ginseng, cordyceps militaris, ginger and wolfberry fruit and preparation method thereof | |
| CN102860510A (en) | Anti-fatigue anti-anoxia health food and preparation method thereof | |
| CN102860495B (en) | Anti-anoxia immunity-improving health food and preparation method thereof | |
| CN102871119A (en) | Health-care food with anti-anoxia effect and preparation method thereof | |
| CN104189038B (en) | Chinese medicine preparation for nursing one's health female pathology health and immunologic function | |
| CN102885305A (en) | Health food composition for enhancing immunity and preparation method thereof | |
| CN113813313A (en) | Tea beverage with effects of dispelling effects of alcohol and protecting liver and preparation method thereof | |
| CN102860509A (en) | Anti-fatigue immunity-improving health food and preparation method thereof | |
| CN101940317B (en) | Health food for improving immunity of human bodies and preparation method thereof | |
| CN102406172B (en) | Health-care food for enhancing immunity and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130313 |